Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;10(4):477-484.e1.
doi: 10.1016/j.jalz.2013.06.003. Epub 2013 Aug 24.

A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank

Affiliations

A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank

Jon B Toledo et al. Alzheimers Dement. 2014 Jul.

Abstract

Neurodegenerative diseases (NDs) are defined by the accumulation of abnormal protein deposits in the central nervous system (CNS), and only neuropathological examination enables a definitive diagnosis. Brain banks and their associated scientific programs have shaped the actual knowledge of NDs, identifying and characterizing the CNS deposits that define new diseases, formulating staging schemes, and establishing correlations between neuropathological changes and clinical features. However, brain banks have evolved to accommodate the banking of biofluids as well as DNA and RNA samples. Moreover, the value of biobanks is greatly enhanced if they link all the multidimensional clinical and laboratory information of each case, which is accomplished, optimally, using systematic and standardized operating procedures, and in the framework of multidisciplinary teams with the support of a flexible and user-friendly database system that facilitates the sharing of information of all the teams in the network. We describe a biobanking system that is a platform for discovery research at the Center for Neurodegenerative Disease Research at the University of Pennsylvania.

Keywords: Alzheimer's Disease; Autopsy; Cerebrospinal fluid; Dementia; Frontotemporal lobar degeneration; Genetics; Neurodegeneration; Parkinson's Disease; Plasma; Serum.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Description of clinical, data, and sample integration in the Neuropathology, Biomarker, and Genetics Biobank. UPenn, University of Pennsylvania; PMC, Penn Memory Center; FTDC, Frontotemporal Dementia Center; PD&MDC, Parkinson’s Disease and Movement Disorder Clinic; ALSC, Amyotrophic Lateral Sclerosis Center.

References

    1. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol. 1998;152:879–84. - PMC - PubMed
    1. Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132:2922–31. - PMC - PubMed
    1. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–3. - PubMed
    1. Buee L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease. Brain Pathol. 1999;9:681–93. - PMC - PubMed
    1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Z Psychiatrie Psychisch-Gerichtliche Med. 1907;64:146–8.

Further readings

    1. Henchcliffe C, Dodel R, Beal MF. Biomarkers of Parkinson’s disease and dementia with Lewy bodies. Prog Neurobiol. 2011;95:601–13. - PubMed
    1. Hu WT, Trojanowski JQ, Shaw LM. Biomarkers in frontotemporal lobar degeneration: progress and challenges. Prog Neurobiol. 2011;95:636–48. - PMC - PubMed
    1. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008;131:1630–45. - PMC - PubMed
    1. Davies DR, Gelinas AD, Zhang C, Rohloff JC, Carter JD, O’Connell D, et al. Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc Natl Acad Sci U S A. 2012;109:19971–6. - PMC - PubMed
    1. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368:117–27. - PMC - PubMed

Publication types

MeSH terms